mepartricin mepartricin mepartricin is a macrolide polyene compound that is useful for urethra, prostate, and bladder function. it has been studied for use in treating chronic pelvic pain syndrome and benign prostatic hyperplasia. mepartricinclinical dataahfs/drugs.cominternational drug namesatc codea01ab16 (who) d01aa06 (who) g01aa09 (who) g04cx03 (who)identifiers iupac name (19e,21e,23z,25z,27e,29e,31e)-methyl 34-((2s,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-1,3,5,7,9,13,37-heptahydroxy-17-(5-hydroxy-7--7-oxoheptan-2-yl)-18-methyl-11,15-dioxo-16,39-dioxabicyclononatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate cas number62534-68-3 ypubchem cid6479653chemspider21106342 yuniil13v8793fqchemblchembl2106426comptox dashboard (epa)dtxsid40872304 echa infocard100.057.786 chemical and physical dataformulac60h88n2o19molar mass1141.359 g·mol−13d model (jsmol)interactive image smiles cnc1ccc(cc1)c(=o)cc(o)ccc(c)c3oc(=o)cc(o)cc(=o)cc(o)cc(o)cc(o)cc(o)cc4(o)cc(o)c(c(=o)oc)c(cc(o2o(c)(o)(n)2o)/c=c/c=c/c=c/c=c\c=c/c=c/c=c/c3c)o4 inchi inchi=1s/c60h88n2o19/c1-36-18-16-14-12-10-8-6-7-9-11-13-15-17-19-48(79-59-56(74)54(61)55(73)38(3)78-59)33-51-53(58(75)77-5)50(71)35-60(76,81-51)34-47(69)30-45(67)28-43(65)26-42(64)27-44(66)29-46(68)32-52(72)80-57(36)37(2)20-25-41(63)31-49(70)39-21-23-40(62-4)24-22-39/h6-19,21-24,36-38,41-43,45-48,50-51,53-57,59,62-65,67-69,71,73-74,76h,20,25-35,61h2,1-5h3/b7-6-,10-8-,11-9+,14-12+,15-13+,18-16+,19-17+/t36?,37?,38-,41?,42?,43?,45?,46?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59+,60?/m1/s1 ykey:gvevtksepquija-pldhrhjxsa-n y (verify) pharmacodynamics mepartricin is an estrogen reabsorption inhibitor that may interfere with the reabsorption of estrogens in the gut leading to increased fecal estrogen excretion. it reduces 17β-estradiol concentration in enterohepatic circulation and decreases estrogen levels in the prostate. the effect of mepartricin on the reabsorption of estrogens was evaluated in studies in vitro and in vivo. mepartricin significantly improves pelvic pain and quality of life compared with the results in placebo group after two months of treatment. regarding to the theory that hormonal disorders could promote prostatic inflammation, mepartricin, that can lower estrogen levels in prostate, is an effective drug in the treatment of patients with chronic pelvic pain syndrome and is referred in 2015 world journal pharmacology updates on therapies for chronic prostatitis/chronic pelvic pain syndrome.